Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34468791 | 0.90 | KDM4E (0.62) | CNR2NPC1RAB9APARP1CNR1 | |
| SCHEMBL16627891 | 0.89 | KDM4E (0.52) | CNR2NPC1RAB9ACNR1KDM4E | |
| SCHEMBL34468766 | 0.88 | SMYD3 (0.49) | CNR2NPC1RAB9APARP1KDM4E | |
| SCHEMBL34468807 | 0.88 | PARP1 (0.50) | CNR2NPC1RAB9APARP1CNR1 | |
| SCHEMBL16627831 | 0.88 | KDM4E (0.51) | CNR2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL16627593 | 0.88 | KDM4E (0.51) | CNR2NPC1RAB9ASMN1; SMN2PARP1 | |
| SCHEMBL16627711 | 0.88 | HTT (0.57) | CNR2SMN1; SMN2CNR1KDM4EALDH1A1 | |
| SCHEMBL16627739 | 0.87 | SMYD3 (0.50) | CNR2NPC1RAB9ACNR1KDM4E | |
| SCHEMBL16627887 | 0.85 | KDM4E (0.48) | CNR2NPC1RAB9ACNR1KDM4E | |
| SCHEMBL16627868 | 0.84 | KDM4E (0.48) | CNR2NPC1KDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090571-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260116873-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE INC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260116873-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2026090571-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2015050379-A1 | NOVEL QUINOLINONE DERIVATIVE AND USE THEREOF | 광주과학기술원 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116873-A1 | APYRASE INHIBITORS | APEH, AP3M1, SRR | CNR2 1217/4885NPC1 3027/4885RAB9A 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.